{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:07:04Z","timestamp":1791670024745,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Reprogramming of cancers into normal-like tissues is an innovative strategy for cancer treatment. Recent reports demonstrate that defined factors can reprogram cancer cells into pluripotent stem cells. Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans. Despite multimodal therapy, the outcome for patients with GBM is still poor. Therefore, developing novel therapeutic strategy is a critical requirement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We have developed a novel reprogramming method that uses a conceptually unique strategy for GBM treatment. We screened a kinase inhibitor library to find which candidate inhibitors under reprogramming condition can reprogram GBM cells into neurons. The induced neurons are identified whether functional and loss of tumorigenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We have found that mTOR and ROCK kinase inhibitors are sufficient to reprogram GBM cells into neural-like cells and \u201cnormal\u201d neurons. The induced neurons expressed neuron-specific proteins, generated action potentials and neurotransmitter receptor-mediated currents. Genome-wide transcriptional analysis showed that the induced neurons had a profile different from GBM cells and were similar to that of control neurons induced by established methods. In vitro and in vivo tumorigenesis assays showed that induced neurons lost their proliferation ability and tumorigenicity. Moreover, reprogramming treatment with ROCK-mTOR inhibitors prevented GBM local recurrence in mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study indicates that ROCK and mTOR inhibitors-based reprogramming treatment prevents GBM local recurrence. Currently ROCK-mTOR inhibitors are used as anti-tumor drugs in patients, so this reprogramming strategy has significant potential to move rapidly toward clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-018-0857-5","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T05:19:00Z","timestamp":1533187140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["RETRACTED ARTICLE: Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors"],"prefix":"10.1186","volume":"37","author":[{"given":"Jie","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Hallahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"key":"857_CR1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861\u201372.","journal-title":"Cell"},{"key":"857_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nature10202","volume":"476","author":"ZP Pang","year":"2011","unstructured":"Pang ZP, Yang N, Vierbuchen T, et al. Induction of human neuronal cells by defined transcription factors. Nature. 2011;476:220\u20133.","journal-title":"Nature"},{"key":"857_CR3","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nature08797","volume":"463","author":"T Vierbuchen","year":"2010","unstructured":"Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010;463:1035\u201341.","journal-title":"Nature"},{"key":"857_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.cell.2011.07.007","volume":"146","author":"L Qiang","year":"2011","unstructured":"Qiang L, Fujita R, Yamashita T, et al. Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell. 2011;146:359\u201371.","journal-title":"Cell"},{"key":"857_CR5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature10284","volume":"476","author":"M Caiazzo","year":"2011","unstructured":"Caiazzo M, Dell'Anno MT, Dvoretskova E, et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature. 2011;476:224\u20137.","journal-title":"Nature"},{"key":"857_CR6","doi-asserted-by":"publisher","first-page":"10343","DOI":"10.1073\/pnas.1105135108","volume":"108","author":"U Pfisterer","year":"2011","unstructured":"Pfisterer U, Kirkeby A, Torper O, et al. Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci U S A. 2011;108:10343\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"857_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nature10323","volume":"476","author":"AS Yoo","year":"2011","unstructured":"Yoo AS, Sun AX, Li L, et al. MicroRNA-mediated conversion of human fibroblasts to neurons. Nature. 2011;476:228\u201331.","journal-title":"Nature"},{"key":"857_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.stem.2011.07.002","volume":"9","author":"R Ambasudhan","year":"2011","unstructured":"Ambasudhan R, Talantova M, Coleman R, et al. Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. Cell Stem Cell. 2011;9:113\u20138.","journal-title":"Cell Stem Cell"},{"key":"857_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.stem.2011.07.014","volume":"9","author":"EY Son","year":"2011","unstructured":"Son EY, Ichida JK, Wainger BJ, et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell. 2011;9:205\u201318.","journal-title":"Cell Stem Cell"},{"key":"857_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.stem.2012.05.018","volume":"11","author":"KL Ring","year":"2012","unstructured":"Ring KL, Tong LM, Balestra ME, et al. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell. 2012;11:100\u20139.","journal-title":"Cell Stem Cell"},{"key":"857_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.stem.2011.09.011","volume":"9","author":"J Kim","year":"2011","unstructured":"Kim J, Su SC, Wang H, et al. Functional integration of dopaminergic neurons directly converted from mouse fibroblasts. Cell Stem Cell. 2011;9:413\u20139.","journal-title":"Cell Stem Cell"},{"key":"857_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00432-016-2258-5","volume":"143","author":"K Izgi","year":"2017","unstructured":"Izgi K, Canatan H, Iskender B. Current status in cancer cell reprogramming and its clinical implications. J Cancer Res Clin Oncol. 2017;143:371\u201383.","journal-title":"J Cancer Res Clin Oncol"},{"key":"857_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrc.2016.12","volume":"16","author":"S Powers","year":"2016","unstructured":"Powers S, Pollack RE. Inducing stable reversion to achieve cancer control. Nat Rev Cancer. 2016;16:266\u201370.","journal-title":"Nat Rev Cancer"},{"key":"857_CR14","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/onc.2012.349","volume":"32","author":"JY Lang","year":"2013","unstructured":"Lang JY, Shi Y, Chin YE. Reprogramming cancer cells: back to the future. Oncogene. 2013;32:2247\u20138.","journal-title":"Oncogene"},{"key":"857_CR15","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1056\/NEJM199105163242002","volume":"324","author":"RP Warrell Jr","year":"1991","unstructured":"Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 1991;324:1385\u201393.","journal-title":"N. Engl. J. Med"},{"key":"857_CR16","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1101\/gad.1213504","volume":"18","author":"K Hochedlinger","year":"2004","unstructured":"Hochedlinger K, Blelloch R, Brennan C, et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 2004;18:1875\u201385.","journal-title":"Genes Dev"},{"key":"857_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.molmed.2012.04.001","volume":"18","author":"V Ramos-Mejia","year":"2012","unstructured":"Ramos-Mejia V, Fraga MF, Menendez P. iPSCs from cancer cells: challenges and opportunities. Trends Mol Med. 2012;18:245\u20137.","journal-title":"Trends Mol Med"},{"key":"857_CR18","doi-asserted-by":"crossref","unstructured":"Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene. 2013;32:2249\u201360. 2260","DOI":"10.1038\/onc.2012.237"},{"key":"857_CR19","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1182\/blood-2009-07-231845","volume":"115","author":"JE Carette","year":"2010","unstructured":"Carette JE, Pruszak J, Varadarajan M, et al. Generation of iPSCs from cultured human malignant cells. Blood. 2010;115:4039\u201342.","journal-title":"Blood"},{"key":"857_CR20","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1242\/jcs.054783","volume":"122","author":"J Utikal","year":"2009","unstructured":"Utikal J, Maherali N, Kulalert W, Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci. 2009;122:3502\u201310.","journal-title":"J Cell Sci"},{"key":"857_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1073\/pnas.0912407107","volume":"107","author":"N Miyoshi","year":"2010","unstructured":"Miyoshi N, Ishii H, Nagai K, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc.Natl.Acad.Sci.U.S.A. 2010;107:40\u20135.","journal-title":"Proc.Natl.Acad.Sci.U.S.A."},{"key":"857_CR22","doi-asserted-by":"publisher","first-page":"e10320","DOI":"10.1371\/journal.pone.0010320","volume":"5","author":"G Chang","year":"2010","unstructured":"Chang G, Miao YL, Zhang Y, et al. Linking incomplete reprogramming to the improved pluripotency of murine embryonal carcinoma cell-derived pluripotent stem cells. PLoS.One. 2010;5:e10320.","journal-title":"PLoS.One"},{"key":"857_CR23","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2011-03-340620","volume":"118","author":"SM Choi","year":"2011","unstructured":"Choi SM, Liu H, Chaudhari P, et al. Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood. 2011;118:1801\u20135.","journal-title":"Blood"},{"key":"857_CR24","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1182\/blood-2010-07-298331","volume":"117","author":"K Hu","year":"2011","unstructured":"Hu K, Yu J, Suknuntha K, et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood. 2011;117:e109\u201319.","journal-title":"Blood"},{"key":"857_CR25","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1261\/rna.1162708","volume":"14","author":"SL Lin","year":"2008","unstructured":"Lin SL, Chang DC, Chang-Lin S, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA. 2008;14:2115\u201324.","journal-title":"RNA"},{"key":"857_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nm.2546","volume":"18","author":"R Amson","year":"2011","unstructured":"Amson R, Pece S, Lespagnol A, et al. Reciprocal repression between P53 and TCTP. Nat Med. 2011;18:91\u20139.","journal-title":"Nat Med"},{"key":"857_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/CCO.0b013e32835b7d21","volume":"25","author":"R Amson","year":"2013","unstructured":"Amson R, Karp JE, Telerman A. Lessons from tumor reversion for cancer treatment. Curr Opin Oncol. 2013;25:59\u201365.","journal-title":"Curr Opin Oncol"},{"key":"857_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/cr.2011.28","volume":"21","author":"B Papp","year":"2011","unstructured":"Papp B, Plath K. Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape. Cell Res. 2011;21:486\u2013501.","journal-title":"Cell Res"},{"key":"857_CR29","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/jcp.22450","volume":"226","author":"R Ho","year":"2011","unstructured":"Ho R, Chronis C, Plath K. Mechanistic insights into reprogramming to induced pluripotency. J Cell Physiol. 2011;226:868\u201378.","journal-title":"J Cell Physiol"},{"key":"857_CR30","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.neuron.2011.05.003","volume":"70","author":"SS Han","year":"2011","unstructured":"Han SS, Williams LA, Eggan KC. Constructing and deconstructing stem cell models of neurological disease. Neuron. 2011;70:626\u201344.","journal-title":"Neuron"},{"key":"857_CR31","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.cell.2012.02.031","volume":"148","author":"AB Cherry","year":"2012","unstructured":"Cherry AB, Daley GQ. Reprogramming cellular identity for regenerative medicine. Cell. 2012;148:1110\u201322.","journal-title":"Cell"},{"key":"857_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nature10761","volume":"481","author":"DA Robinton","year":"2012","unstructured":"Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481:295\u2013305.","journal-title":"Nature"},{"key":"857_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11060-011-0793-0","volume":"108","author":"FE Bleeker","year":"2012","unstructured":"Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neurooncol. 2012;108:11\u201327.","journal-title":"J Neurooncol."},{"key":"857_CR34","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","volume":"23","author":"AF Tamimi","year":"2014","unstructured":"Tamimi AF, Juweid M, Thakkar JP, et al. Epidemiology and Outcome of Glioblastoma. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23:1985\u201396.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"857_CR35","first-page":"121","volume":"3","author":"RM Young","year":"2015","unstructured":"Young RM, Jamshidi A, Davis G, Sherman JH. Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med. 2015;3:121\u20135839.","journal-title":"Ann Transl Med"},{"key":"857_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11060-017-2507-8","volume":"134","author":"Y Qin","year":"2017","unstructured":"Qin Y, Takahashi M, Sheets K, et al. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. J Neurooncol. 2017;134:29\u201340.","journal-title":"J Neurooncol"},{"key":"857_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11060-012-1008-z","volume":"111","author":"S Hingtgen","year":"2013","unstructured":"Hingtgen S, Figueiredo JL, Farrar C, et al. Real-time multi-modality imaging of glioblastoma tumor resection and recurrence. J Neurooncol. 2013;111:153\u201361.","journal-title":"J Neurooncol."},{"key":"857_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nn.3019","volume":"15","author":"TM Kauer","year":"2011","unstructured":"Kauer TM, Figueiredo JL, Hingtgen S, Shah K. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci. 2011;15:197\u2013204.","journal-title":"Nat Neurosci"},{"key":"857_CR39","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1158\/1078-0432.CCR-06-0438","volume":"12","author":"EI Fomchenko","year":"2006","unstructured":"Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res. 2006;12:5288\u201397.","journal-title":"Clin Cancer Res"},{"key":"857_CR40","doi-asserted-by":"publisher","first-page":"e00063","DOI":"10.1042\/AN20110014","volume":"3","author":"VL Jacobs","year":"2011","unstructured":"Jacobs VL, Valdes PA, Hickey WF, De Leo JA. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN.Neuro. 2011;3:e00063.","journal-title":"ASN.Neuro"},{"key":"857_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2007.07.003","volume":"130","author":"M Collado","year":"2007","unstructured":"Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130:223\u201333.","journal-title":"Cell"},{"key":"857_CR42","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000167806","volume":"122","author":"Q Yang","year":"2008","unstructured":"Yang Q. Cellular senescence, telomere recombination and maintenance. Cytogenet Genome Res. 2008;122:211\u20138.","journal-title":"Cytogenet Genome Res"},{"key":"857_CR43","doi-asserted-by":"publisher","first-page":"11677","DOI":"10.1158\/0008-5472.CAN-07-1390","volume":"67","author":"Q Yang","year":"2007","unstructured":"Yang Q, Zhang R, Horikawa I, et al. Functional diversity of human protection of telomeres 1 isoforms in telomere protection and cellular senescence. Cancer Res. 2007;67:11677\u201386.","journal-title":"Cancer Res"},{"key":"857_CR44","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1093\/emboj\/cdg417","volume":"22","author":"CM Beausejour","year":"2003","unstructured":"Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003;22:4212\u201322.","journal-title":"EMBO J"},{"key":"857_CR45","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.cell.2005.02.003","volume":"120","author":"J Campisi","year":"2005","unstructured":"Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005;120:513\u201322.","journal-title":"Cell"},{"key":"857_CR46","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/nature08285","volume":"460","author":"J Utikal","year":"2009","unstructured":"Utikal J, Polo JM, Stadtfeld M, et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature. 2009;460:1145\u20138.","journal-title":"Nature"},{"key":"857_CR47","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/nature08290","volume":"460","author":"H Li","year":"2009","unstructured":"Li H, Collado M, Villasante A, et al. The Ink4\/Arf locus is a barrier for iPS cell reprogramming. Nature. 2009;460:1136\u20139.","journal-title":"Nature"},{"key":"857_CR48","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1038\/ncomms5112","volume":"5","author":"CK Sun","year":"2014","unstructured":"Sun CK, Zhou D, Zhang Z, et al. Senescence impairs direct conversion of human somatic cells to neurons. Nat Commun. 2014;5:4112.","journal-title":"Nat Commun"},{"key":"857_CR49","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.celrep.2014.11.040","volume":"9","author":"D Zhou","year":"2014","unstructured":"Zhou D, Zhang Z, He LM, et al. Conversion of fibroblasts to neural cells by p53 depletion. Cell Rep. 2014;9:2034\u201342.","journal-title":"Cell Rep"},{"key":"857_CR50","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/j.1478-3231.2010.02232.x","volume":"30","author":"CC Wong","year":"2010","unstructured":"Wong CC, Wong CM, Au SL, Ng IO. RhoGTPases and rho-effectors in hepatocellular carcinoma metastasis: ROCK N'Rho move it. Liver Int. 2010;30:642\u201356.","journal-title":"Liver Int"},{"key":"857_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/156800910791054202","volume":"10","author":"S Micuda","year":"2010","unstructured":"Micuda S, Rosel D, Ryska A, Brabek J. ROCK inhibitors as emerging therapeutic candidates for sarcomas. CurrCancer Drug Targets. 2010;10:127\u201334.","journal-title":"CurrCancer Drug Targets"},{"key":"857_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-008-9170-7","volume":"28","author":"S Narumiya","year":"2009","unstructured":"Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009;28:65\u201376.","journal-title":"Cancer Metastasis Rev"},{"key":"857_CR53","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ceb.2008.01.002","volume":"20","author":"MF Olson","year":"2008","unstructured":"Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20:242\u20138.","journal-title":"Curr Opin Cell Biol"},{"key":"857_CR54","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/j.1474-9726.2011.00722.x","volume":"10","author":"T Chen","year":"2011","unstructured":"Chen T, Shen L, Yu J, et al. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell. 2011;10:908\u201311.","journal-title":"Aging Cell"},{"key":"857_CR55","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.4161\/cc.10.21.18128","volume":"10","author":"JA Menendez","year":"2011","unstructured":"Menendez JA, Vellon L, Oliveras-Ferraros C, Cufi S, Vazquez-Martin A. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle. 2011;10:3658\u201377.","journal-title":"Cell Cycle"},{"key":"857_CR56","doi-asserted-by":"crossref","unstructured":"Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev; 2013;23:53\u201362.","DOI":"10.1016\/j.gde.2012.12.005"},{"key":"857_CR57","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nature08981","volume":"464","author":"M Kaeberlein","year":"2010","unstructured":"Kaeberlein M. Lessons on longevity from budding yeast. Nature. 2010;464:513\u20139.","journal-title":"Nature"},{"key":"857_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-61779-430-8_1","volume":"821","author":"T Weichhart","year":"2012","unstructured":"Weichhart T. Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life. Methods Mol Biol. 2012;821:1\u201314.","journal-title":"Methods Mol Biol"},{"key":"857_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1098\/rstb.2010.0198","volume":"366","author":"MA McCormick","year":"2011","unstructured":"McCormick MA, Tsai SY, Kennedy BK. TOR and ageing: a complex pathway for a complex process. Philos.Trans.R.Soc.Lond B Biol Sci. 2011;366:17\u201327.","journal-title":"Philos.Trans.R.Soc.Lond B Biol Sci"},{"key":"857_CR60","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nature08221","volume":"460","author":"DE Harrison","year":"2009","unstructured":"Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392\u20135.","journal-title":"Nature"},{"key":"857_CR61","doi-asserted-by":"publisher","first-page":"110743","DOI":"10.18632\/oncotarget.22500","volume":"8","author":"C Abbruzzese","year":"2017","unstructured":"Abbruzzese C, Catalogna G, Gallo E, et al. The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme. Oncotarget. 2017;8:110743\u201355.","journal-title":"Oncotarget"},{"key":"857_CR62","doi-asserted-by":"publisher","first-page":"15868","DOI":"10.18632\/oncotarget.7520","volume":"7","author":"C Talarico","year":"2016","unstructured":"Talarico C, Dattilo V, D'Antona L, et al. SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. Oncotarget. 2016;7:15868\u201384.","journal-title":"Oncotarget"},{"key":"857_CR63","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/ijc.31209","volume":"142","author":"R Agrawal","year":"2018","unstructured":"Agrawal R, Garg A, Benny MP, Sharma V, Sarkar C, Kulshreshtha R. p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment. Int J Cancer. 2018;142:1817\u201328.","journal-title":"Int J Cancer"},{"key":"857_CR64","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.stem.2017.06.004","volume":"21","author":"NI Park","year":"2017","unstructured":"Park NI, Guilhamon P, Desai K, et al. ASCL1 reorganizes chromatin to direct neuronal fate and suppress Tumorigenicity of glioblastoma stem cells. Cell Stem Cell. 2017;21:209\u201324.","journal-title":"Cell Stem Cell"},{"key":"857_CR65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/stem.1767","volume":"33","author":"PO Guichet","year":"2015","unstructured":"Guichet PO, Guelfi S, Teigell M, et al. Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells. Stem Cells. 2015;33:21\u201334.","journal-title":"Stem Cells"},{"key":"857_CR66","doi-asserted-by":"publisher","first-page":"14520","DOI":"10.1073\/pnas.1308610110","volume":"110","author":"J Hu","year":"2013","unstructured":"Hu J, Ho AL, Yuan L, et al. From the cover: neutralization of terminal differentiation in gliomagenesis. Proc Natl Acad Sci USA. 2013;110:14520\u20137.","journal-title":"Proc Natl Acad Sci USA"}],"updated-by":[{"DOI":"10.1186\/s13046-021-02172-6","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"record-id":"34137"},{"DOI":"10.1186\/s13046-018-0857-5","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000}},{"DOI":"10.1186\/s13046-021-02172-6","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0857-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-018-0857-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0857-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:12:16Z","timestamp":1772021536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-018-0857-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["857"],"URL":"https:\/\/doi.org\/10.1186\/s13046-018-0857-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]},"assertion":[{"value":"23 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Editor's Note: The Editor-in-Chief is currently investigating this article as the authorship is under dispute, and concerns have been identified regarding ethics approval for animal research and data sharing. Further editorial action will be taken as appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-021-02172-6","URL":"https:\/\/doi.org\/10.1186\/s13046-021-02172-6","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"181"}}